ReWalk Robotics

ReWalk Robotics
Name	ReWalk Robotics
Type	Public
Founded	2001
Founder	Dr. Amit Goffer
Headquarters	Yokneam Illit, Israel; Marlborough, Massachusetts
Products	Powered exoskeletons
Industry	Medical devices

ReWalk Robotics is a medical device company that developed powered exoskeleton systems for individuals with spinal cord injury and other mobility impairments. The company designed wearable robotic suits to enable upright mobility, standing, and walking, aiming to improve rehabilitation and quality of life for patients and users. ReWalk Robotics' developments intersect with research institutions, hospitals, and regulatory agencies in translational medical technology and rehabilitation engineering.

History

Founded in 2001 by Dr. Amit Goffer, an Israeli inventor and entrepreneur, the company evolved from academic research on powered orthoses at institutions linked to Technion – Israel Institute of Technology and private laboratories. Early funding rounds included support from venture capital firms and programs associated with Yozma-related investors and Israeli incubators. The company expanded operations with offices in Yokneam Illit and later established a commercial presence in Marlborough, Massachusetts to engage with Massachusetts General Hospital, Spaulding Rehabilitation Hospital, and other North American clinical partners. ReWalk Robotics pursued public listings and engaged with capital markets, culminating in an initial public offering and subsequent trading on stock exchanges that attracted attention from institutional investors, analysts at Goldman Sachs, Morgan Stanley, and healthcare-focused funds. Strategic collaborations and licensing negotiations involved medical device companies, academic rehabilitation centers, and nonprofit organizations representing veterans and spinal cord injury communities such as the Paralyzed Veterans of America.

Products and Technology

ReWalk developed a family of powered exoskeleton systems combining battery-powered motors, sensor arrays, and control algorithms. Key components included embedded processors, inertial measurement units, custom battery packs, and modular brace elements integrated with materials suppliers and component manufacturers. Design work drew on concepts used in robotics research at Massachusetts Institute of Technology, Johns Hopkins University, and European robotics groups. Product variants were tailored for clinical rehabilitation settings, home use, and training programs; models addressed different levels of spinal cord lesion and were tested alongside assistive devices such as wheelchairs from companies like Permobil and Invacare. Software and firmware updates involved partnerships with embedded systems firms and biomechanical modeling teams connected to Harvard Medical School and Stanford University laboratories. ReWalk’s technology competed with other exoskeleton developers including Ekso Bionics, Cyberdyne, and research prototypes from institutions like ETH Zurich and University of Tokyo.

Clinical Applications and Trials

Clinical adoption and evidence development relied on trials conducted at rehabilitation centers and academic hospitals. Investigations addressed mobility outcomes, cardiovascular fitness, bone density, and secondary complications of immobility in cohorts drawn from Veterans Affairs medical centers, private clinics, and university hospitals such as Sheba Medical Center and Moss Rehab. Studies were reported in peer-reviewed journals and conference proceedings presented at venues like the International Conference on Rehabilitation Robotics and meetings of the American Congress of Rehabilitation Medicine. Randomized trials, cohort studies, and feasibility studies evaluated gait metrics, oxygen consumption, and user-reported outcomes, often comparing ReWalk use to conventional physiotherapy and robotic gait trainers such as the Lokomat. Collaborations included clinical investigators affiliated with University of Pennsylvania, University College London, and Tel Aviv University.

Regulatory Approval and Safety

ReWalk pursued regulatory clearance pathways across multiple jurisdictions, submitting data to agencies including the U.S. Food and Drug Administration and the European Medicines Agency-linked notified bodies for medical devices under CE marking. The company obtained approvals for specified indications and labeling, with conditions related to training, clinical supervision, and postmarket surveillance. Safety considerations addressed fall risk, skin integrity, battery safety, and device malfunctions; these were managed through user training programs conducted with rehabilitation clinicians, certified trainers from centers such as Spaulding Rehabilitation Hospital, and documentation aligning with standards from International Organization for Standardization committees on medical electrical equipment. Postmarket reporting and safety communications involved exchanges with national competent authorities and healthcare providers.

Business and Financials

ReWalk’s commercial strategy targeted direct sales to hospitals, rehabilitation centers, and specialty clinics as well as rental and training programs. Revenue streams included device sales, service contracts, consumables, and training fees. Financial performance was influenced by reimbursement frameworks involving payers such as private insurers and national health services, procurement decisions at large rehabilitation hospitals, and grant funding from agencies like the Israel Innovation Authority and research grants from institutions such as the National Institutes of Health. Market competition and capital constraints affected pricing strategies and partnership negotiations with distributors and clinical networks including chains of rehabilitation providers.

Criticism and Controversies

Critiques of ReWalk’s approach emerged from stakeholders concerned with cost-effectiveness, long-term clinical benefit, and equitable access. Debates took place in academic forums, policy discussions at healthcare conferences, and among advocacy groups such as United Spinal Association and veterans’ organizations. Regulatory scrutiny, litigation risks, and media coverage involved comparisons to rival companies and highlighted challenges in reimbursement policies, the high capital cost for hospitals, and limitations in the technology’s applicability to patients with different levels of impairment. Ethical discussions referenced standards articulated by bodies like World Health Organization and raised questions about prioritization of novel devices versus traditional rehabilitation resources.

Category:Medical device companies